The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.
Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
5 Perspectives on Laser Treatment in Dermatology
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Recent Povorcitinib 2b Study Shows Improved Repigmentation